Top

Published in:

02-09-2022 | Literatur kommentiert

Nebenwirkungsprofil einer frühen Immuntherapie nach Radiotherapie: eine gepoolte Analyse von Studien in der Datenbank der US Food and Drug Administration

Authors: Lukas Seiß, Univ.-Prof. Dr. med. Thomas Brunner

Published in: Strahlentherapie und Onkologie | Issue 11/2022

Auszug

Anscher MS, Arora S, Weinstock C et al (2022). Association of radiation therapy with risk of adverse events in patients receiving immunotherapy. A pooled analysis of trials in the US Food and Drug Administration database. JAMA Oncol 8(2):232–240. https://doi.org/10.1001/jamaoncol.2021.6439. …

Verma V, Cushman TR, Tang C, Welsh JW (2018) Toxicity of radiation and immunotherapy combinations. Adv Radiat Oncol 3(4):506–511CrossRef

Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, Aizer AA (2018) Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol 4(8):1123–1124CrossRef

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895–903CrossRef

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929CrossRef

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203CrossRef

Title: Nebenwirkungsprofil einer frühen Immuntherapie nach Radiotherapie: eine gepoolte Analyse von Studien in der Datenbank der US Food and Drug Administration
Authors: Lukas Seiß
Univ.-Prof. Dr. med. Thomas Brunner
Publication date: 02-09-2022
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 11/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-01995-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Nebenwirkungsprofil einer frühen Immuntherapie nach Radiotherapie: eine gepoolte Analyse von Studien in der Datenbank der US Food and Drug Administration

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 11/2022

Selective local postoperative radiotherapy for T3–T4 N0 laryngeal cancer

Impact of a ketogenic diet intervention during radiotherapy on body composition: V. Final results of the KETOCOMP study for head and neck cancer patients

Intensity-modulated radiotherapy does not induce volumetric changes of the Bichat fat pad in nasopharyngeal cancer

ORATOR2-Studie – randomisierter Vergleich einer primären Operation oder primären Strahlentherapie bei HPV-positivem Oropharynxkarzinom im Kontext einer Therapiedeeskalation

Ist die elektive Bestrahlung der Lymphknotenlevel IV und Vb bei Nasopharynxkarzinomen erforderlich?

Radio(chemo)therapy in anaplastic thyroid cancer—high locoregional but low distant control rates—a monocentric analysis of a tertiary referral center